Curiox Biosystems

About Curiox Biosystems

Curiox Biosystems, established in 2008 by co-founders Namyong Kim, Ph.D., and Alex Y. K. Kim, operates within the life sciences sector, specifically focusing on sample preparation for suspension cell analysis. The company addresses inefficiencies in traditional cell washing methods, which often rely on centrifugation—a process that can lead to cell loss and compromised sample integrity. Its core business revolves around providing instrumentation and consumables to academic, pharmaceutical, and clinical research laboratories that work with cell-based assays like flow cytometry. Revenue is generated through the sale of its proprietary Laminar Wash™ systems and associated consumables.

The company's foundational technology, Laminar Wash™, automates the cell washing process by gently removing supernatant and contaminants without pelleting the cells through centrifugation. This method improves data quality by minimizing cell stress and ensuring higher cell retention, leading to more consistent and reproducible results in downstream applications. Curiox offers a range of products built on this technology, from manual systems for low-throughput needs to fully automated, walk-away systems designed for high-throughput screening environments. The automated platforms integrate seamlessly into existing lab workflows, providing a hands-off solution for sample preparation. This approach is particularly beneficial for researchers dealing with rare or delicate cell types, where preserving every cell is critical for accurate analysis.

Co-founder and CEO Namyong Kim brings over two decades of experience in the life sciences and diagnostics industry to the company. His journey includes roles in R&D and business development at companies like Samsung and Digital Bio, which provided him with a deep understanding of the market's technical and commercial needs. This background was instrumental in identifying the workflow bottlenecks in cell analysis and developing the Laminar Wash™ technology to address them. A significant milestone for Curiox was its successful initial public offering on the KOSDAQ exchange in South Korea in 2023, a move that secured capital for further expansion and technological development.